DSIP
5mg
- Ships same or next day Orders before 3PM EST, FedEx 2-Day Air
- Verify this lot View the lab reports · View the Vanguard certificate
- Real U.S. support Live chat and email, 7 days a week
For research use only. Not for human or veterinary consumption.
Certified-Pep only sells U.S.-made peptides and products.
Key Features:
Made in the USA
Batch tested at a verifiable U.S. laboratory for identity, content and purity
Screened for endotoxins, heavy metals and sterility
Rigorous quality testing on every batch
All products are delivered in lyophilized powder form
For laboratory and research use only
- PURITY: 99%+
- CAS: 62568-57-4
- FORM: LYOPHILIZED POWDER
- DOSAGE: 5 MG
- PURITY: 99%+
| DSIP 5MG | |
|---|---|
| SKU | CP_DSIP_5MG_3ML_VIAL |
| CATEGORY | Research Compounds |
| CAS | 62568-57-4 |
| VIAL SIZE | 3 mL |
| FORM | LYOPHILIZED POWDER |
| MOLECULAR WEIGHT | 848.82 g/mol |
| SEQUENCE | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| MOLECULAR FORMULA | C35H48N10O15 |
| ITEM ID | 11681 |
Tukhovskaya et al. (2021) investigated DSIP in a rat model of focal stroke induced by intraluminal middle cerebral artery occlusion (MCAO). DSIP was administered over an 8-day course beginning prior to occlusion and continuing through reperfusion. A battery of behavioral assessments – including rotarod testing for motor coordination and balance – was performed at multiple time points over 21 days. Brain infarction volume was measured from serial cryosections at study termination. The authors reported that DSIP-treated animals showed significantly accelerated recovery of motor performance on the rotarod test compared to vehicle-treated controls, although the difference in brain infarction volume did not reach statistical significance [1].
Sale